InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 a.m. EDT
Portfolio Pulse from Benzinga Newsdesk
InspireMD presented one-year follow-up results from the C-GUARDIANS US IDE trial of CGuard at LINC 2024. The results were shared on May 28 at 8:53 a.m. EDT.
May 28, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InspireMD presented positive one-year follow-up results from the C-GUARDIANS US IDE trial of CGuard at LINC 2024, which could boost investor confidence.
The presentation of positive one-year follow-up results from a significant trial can enhance investor confidence in InspireMD's product, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100